POLITICS

'Pharma Bro' Martin Shkreli Backs Bush

Poor Jeb.
Martin Shkreli, ex-CEO of Turing Pharmaceuticals, likely smirking at the thought of a Jeb Bush presidency while appearin
Martin Shkreli, ex-CEO of Turing Pharmaceuticals, likely smirking at the thought of a Jeb Bush presidency while appearing at a congressional hearing on Thursday.

Martin Shkreli, the disgraced ex-CEO of Turing Pharmaceuticals, revealed on Friday night that he is backing the presidential candidacy of former Florida Gov. Jeb Bush.

Shkreli, who achieved national notoriety for jacking up the price of a rare life-saving medication and expressing a complete lack of contrition for it -- a feat that earned him the nickname "Pharma Bro" -- announced his support for the struggling Republican contender in a tweet directed at Bush.

Shkreli's backing apparently only goes so far; a look at his political donations on OpenSecrets.org shows that he has not contributed to Bush's campaign -- though it is not clear if he has given to Right to Rise USA, the Super PAC backing Bush.

The entrepreneur was indicted in December for alleged securities fraud unrelated to the price gouging controversy. 

The endorsement of one of the country's most despised corporate villains is surely an unwelcome development for the struggling Bush campaign. 

His campaign may be more pleased with the gushing support of former NFL star Chad "Ochocinco" Johnson.

Initially a favorite of the Republican party's business-friendly establishment wing and elite donor class, Bush has failed to break through in this year's populism-tinged primary race.

In New Hampshire, where Bush's campaign had pinned its hopes for a comeback, the former Florida governor enjoys the support of just 8.8 percent of Republicans ahead of Tuesday's first-in-the-nation primary, according to HuffPost Pollster's polling average. He trails Donald Trump, Marco Rubio, John Kasich and Ted Cruz in the Granite State.

Also on HuffPost:

PHOTO GALLERY
Martin Shkreli Faces
testPromoTitleReplace testPromoDekReplace Join HuffPost Today! No thanks.
CONVERSATIONS